MDS Trials

Addition of gemtuzumab ozogamicin to induction chemotherapy

We summarize several presentations from ASH 2022 on the impact of gemtuzumab ozogamicin plus chemotherapy and fractionated versus single...

Updates from NCRI AML18 and AML19 trials

During the 2nd National Cancer Research Institute (NCRI) acute myeloid leukemia (AML) Academy Meeting, Nigel Russell presented updated data on the ongoing NCRI...

Health-related quality of life in patients with MDS

The article summarizes the factors influencing HRQoL and how HRQoL is measured in patients with MDS.

Editorial theme | Supportive care for MDS

As part of our editorial theme looking at supportive care in MDS, here, we summarize a study by Garelius et al., which analyzed patients registered in the...

Novel treatment strategies in patients with high-risk and low-risk MDS

We summarize key updates from ASH 2022 on the promising outcomes of sabatolimab in high-risk MDS patients, as well as imetelstat...

Real-world validation of the IPSS-M risk stratification model for MDS and comparison to IPSS-R

The MDS Hub summarizes several presentations from ASH 2022 discussing the implementation of IPSS-M and...

Latest insights on TP53 mutations in AML and MDS from ASH 2022

In this article, we summarize several presentations from the 64th ASH Annual Meeting and Exposition on TP53mut and the impact on survival...

Decitabine plus cedazuridine approved by the FDA for MDS

On July 7, 2020, the U.S. Food and Drug Administration (FDA) approved the oral combination of decitabine with cedazuridine (ASTX727) to treat...